Nothing Special   »   [go: up one dir, main page]

DK1910521T3 - Generering af allo-begrænsede, antigenspecifikke T-celler - Google Patents

Generering af allo-begrænsede, antigenspecifikke T-celler

Info

Publication number
DK1910521T3
DK1910521T3 DK06776623.8T DK06776623T DK1910521T3 DK 1910521 T3 DK1910521 T3 DK 1910521T3 DK 06776623 T DK06776623 T DK 06776623T DK 1910521 T3 DK1910521 T3 DK 1910521T3
Authority
DK
Denmark
Prior art keywords
cells
specific
antigen
allo
generation
Prior art date
Application number
DK06776623.8T
Other languages
English (en)
Inventor
Dolores Schendel
Susanne Wilde
Thomas Blankenstein
Original Assignee
Helmholtz Zentrum Muenchen
Max Delbrueck Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen, Max Delbrueck Centrum filed Critical Helmholtz Zentrum Muenchen
Application granted granted Critical
Publication of DK1910521T3 publication Critical patent/DK1910521T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DK06776623.8T 2005-08-05 2006-08-04 Generering af allo-begrænsede, antigenspecifikke T-celler DK1910521T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05017128 2005-08-05
EP06007539 2006-04-10
PCT/EP2006/007752 WO2007017201A1 (en) 2005-08-05 2006-08-04 Generation of antigen specific t cells

Publications (1)

Publication Number Publication Date
DK1910521T3 true DK1910521T3 (da) 2011-02-07

Family

ID=37598202

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06776623.8T DK1910521T3 (da) 2005-08-05 2006-08-04 Generering af allo-begrænsede, antigenspecifikke T-celler
DK10179257.0T DK2327763T3 (da) 2005-08-05 2006-08-04 Antigen generation af specifikke T-celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10179257.0T DK2327763T3 (da) 2005-08-05 2006-08-04 Antigen generation af specifikke T-celler

Country Status (11)

Country Link
US (2) US8486694B2 (da)
EP (3) EP2327763B1 (da)
JP (3) JP5079697B2 (da)
AT (1) ATE484578T1 (da)
DE (1) DE602006017556D1 (da)
DK (2) DK1910521T3 (da)
ES (2) ES2672895T3 (da)
HU (1) HUE038833T2 (da)
PL (1) PL2327763T3 (da)
PT (1) PT2327763T (da)
WO (1) WO2007017201A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
AU2009317161B2 (en) 2008-11-24 2014-09-11 Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
EP2393833A1 (en) * 2009-02-09 2011-12-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
US9181527B2 (en) 2009-10-29 2015-11-10 The Trustees Of Dartmouth College T cell receptor-deficient T cell compositions
PT2618835T (pt) * 2010-09-20 2017-08-08 Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Epítopos de célula t e recetores de célula t específicos de antigénio
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
PL3392270T3 (pl) * 2011-09-15 2021-03-08 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Receptory komórek T rozpoznające MAGE ograniczone do HLA-A1 lub HLA-CW7
US9790278B2 (en) 2012-05-07 2017-10-17 The Trustees Of Dartmouth College Anti-B7-H6 antibody, fusion proteins, and methods of using the same
IL302514A (en) * 2012-06-11 2023-07-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
CA2883673A1 (en) 2012-09-05 2014-03-13 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
AU2014351871B2 (en) 2013-11-22 2020-02-13 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
US20170081635A1 (en) * 2014-03-20 2017-03-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
CA2963364A1 (en) * 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
WO2016071343A1 (en) 2014-11-03 2016-05-12 Immures S.R.L. T cell receptors
EP3215535A2 (en) * 2014-11-05 2017-09-13 Board of Regents, The University of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
SG10201913978RA (en) * 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors
KR102668219B1 (ko) 2015-03-16 2024-05-28 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법
CA2987871A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
CA2987857A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh T cell receptor library
EP3328399B1 (en) 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
CA2998869A1 (en) * 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394247B1 (en) 2015-12-23 2021-02-10 Medigene Immunotherapies GmbH Novel generation of antigen-specific tcrs
CN109310709A (zh) * 2015-12-30 2019-02-05 细胞基因公司 T淋巴细胞生产方法和由此产生的t淋巴细胞
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3516044A4 (en) * 2016-09-23 2020-03-11 Fred Hutchinson Cancer Research Center SPECIFIC TCRs OF THE MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
AU2019225798B2 (en) 2018-02-26 2023-05-18 Medigene Immunotherapies Gmbh Nyeso tcr
EP3849569A4 (en) * 2018-09-10 2022-06-08 Torque Therapeutics, Inc. ANTIGEN-SPECIFIC T LYMPHOCYTES AND METHODS OF MAKING AND USING THEM
WO2020069452A1 (en) * 2018-09-27 2020-04-02 Genocea Biosciences, Inc. Treatment methods
JP2022511974A (ja) * 2018-12-12 2022-02-01 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫抑制のための組成物および方法
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
JP6878544B2 (ja) * 2019-10-02 2021-05-26 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP7340144B2 (ja) * 2019-10-02 2023-09-07 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
CN115397863A (zh) 2020-04-01 2022-11-25 基因医疗免疫疗法有限责任公司 Cd3融合蛋白及其用途
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP4200401B1 (en) 2020-08-18 2024-07-24 Medigene Immunotherapies GmbH Enrichment of t cells using an anti-cbeta antibody
EP4217380A1 (en) 2020-09-24 2023-08-02 Medigene Immunotherapies GmbH Prame specific t-cell receptors and uses thereof
WO2023175070A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library
WO2023175069A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69723230T2 (de) * 1996-01-17 2004-05-27 Imperial College Innovations Ltd. Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
ES2267937T3 (es) * 2002-08-23 2007-03-16 Deutsches Rheuma-Forschungszentrum Berlin Procedimiento de deteccion y aislamiento de linfocitos t que reconocen un antigeno definido.
DK1910521T3 (da) * 2005-08-05 2011-02-07 Helmholtz Zentrum Muenchen Generering af allo-begrænsede, antigenspecifikke T-celler

Also Published As

Publication number Publication date
WO2007017201A1 (en) 2007-02-15
JP2009502185A (ja) 2009-01-29
ES2672895T3 (es) 2018-06-18
EP2327763B1 (en) 2018-03-14
EP1910521B1 (en) 2010-10-13
HUE038833T2 (hu) 2018-11-28
EP1910521A1 (en) 2008-04-16
ATE484578T1 (de) 2010-10-15
EP3369812A1 (en) 2018-09-05
DE602006017556D1 (de) 2010-11-25
US20140141026A1 (en) 2014-05-22
JP2012213402A (ja) 2012-11-08
DK2327763T3 (da) 2018-05-22
PT2327763T (pt) 2018-05-11
EP2327763A1 (en) 2011-06-01
ES2842878T3 (es) 2021-07-15
PL2327763T3 (pl) 2018-08-31
EP3369812B1 (en) 2020-10-07
JP5079697B2 (ja) 2012-11-21
US8486694B2 (en) 2013-07-16
US20100189728A1 (en) 2010-07-29
JP2016135127A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
DK1910521T3 (da) Generering af allo-begrænsede, antigenspecifikke T-celler
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
Tian et al. Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection
Ryan et al. Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation
Stephens et al. Curing CNS autoimmune disease with myelin‐reactive Foxp3+ Treg
WO2005004592A8 (en) Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
Yee Adoptive T cell therapy: addressing challenges in cancer immunotherapy
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
CY1114047T1 (el) Νεοι φορεις εκφρασης και χρησεις αυτων
CY1114755T1 (el) Ρυθμιση των τ κυτταρων
BR112014006176A8 (pt) Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada
DK1483294T3 (da) Internaliserende anti-CD74-antistoffer og fremgangsmåder til deres anvendelse
Yamaki et al. OX40 and IL‐7 play synergistic roles in the homeostatic proliferation of effector memory CD4+ T cells
Pang et al. Current progress of CAR-NK therapy in cancer treatment
Moon et al. Use of epigenetic modification to induce FOXP3 expression in naïve T cells
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
Charron et al. Immunogenicity and allogenicity: a challenge of stem cell therapy
Wang et al. Repeated long‐term DT application in the DEREG mouse induces a neutralizing anti‐DT antibody response
DK1788078T3 (da) Dendritisk celle-lægemiddel indeholdende den dendritiske celle, terapeutisk fremgangsmåde under anvendelse af den dendritiske celle og fremgangsmåde til dyrkning af gammadelta-T-celle
DK1572133T3 (da) Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+
Sun et al. Foxp3 regulates human natural CD4+ CD25+ regulatory T‐cell‐mediated suppression of xenogeneic response
Lawrence Human iPS cells for clinical applications and cellular products
Colonna et al. Natural and expanded CD4+ CD25+ regulatory T cells in bone marrow transplantation
Cai et al. Commentary: PIRs mediate innate myeloid cell memory to nonself MHC molecules